Antipsychotics: improving their efficacy, reducing adverse effects. Case study series. Part 2nd Review article

Main Article Content

Maja Polikowska
Bartosz Łoza

Abstract

Antipsychotics, which were introduced in 1952, and atypical antipsychotics, introduced in 1988, are characterized mostly by their efficacy-to-safety balance. Both, efficacy and safety features, can be combined into one effectiveness concept. This approach is decisive in relation to the outcomes of short and long-term therapy. It is common that questions about clinical advantages of any single antipsychotic are being raised when we want to administer that medicine. Actually, the antipsychotic effectiveness is usually individual. We report the case series of patients, treated successfully with various antipsychotics (olanzapine, aripiprazole, quetiapine). The main idea of this series is to depict the constant therapeutic effort to balance the combined efficacy-tolerance effects.

Article Details

Section
Articles

References

1. Kane JM, Schooler NR, Marcy P et al. The RAISE early treatment program for first-episode psychosis: background, rationale, and study design. J Clin Psychiatry. 2015; 76: 240-246. Abstract.
2. Srihari VH, Tek C, Pollard J et al. Reducing the duration of untreated psychosis and its impact in the U.S.: the STEP-ED study. BMC Psychiatry 2014; 14: 335.
3. FDA, Food and Drug Administration.
4. Drake RE, Essock SM, Shaner A et al. Implementing dual diagnosis services for clients with severe mental illness. Psychiatric Services 2001; 54(1): 469-476.
5. Henderson DC, Fan X, Copeland PM et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol 2009; 29(2): 165-169.
6. Łoza B. Problemy metaboliczne chorych na schizofrenię i zaburzenie dwubiegunowe. W: Mamcarz A (ed). Zespół metaboliczny. Wydanie II rozszerzone. Medical Education, Warszawa 2008: 587-602.